Literature DB >> 6209186

Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion.

B Göke, F Stöckmann, R Müller, P G Lankisch, W Creutzfeldt.   

Abstract

Camostate, a synthetic serine protease inhibitor, specifically inhibits the trypsin activity in vitro. Immediately after intravenous administration of camostate (5, 2.5, 0.5, and 0.1 mg/kg body weight/h) the trypsin activity in the biliary-pancreatic juice was diminished dose-dependently in anaesthetized rats. The amylase release was not influenced. Camostate and its metabolites were detected by high-pressure liquid chromatography in the pancreatic juice and tissue; in plasma, only the metabolites were found. Therefore, the inhibitory action of camostate on the trypsin activity in the biliary-pancreatic juice may be due to penetration of camostate into the juice.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209186     DOI: 10.1159/000199102

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  9 in total

1.  Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice.

Authors:  Kamal Albarazanji; Matthew Jennis; Cassandre R Cavanaugh; Wensheng Lang; Bhanu Singh; James C Lanter; James M Lenhard; Pamela J Hornby
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-03-28       Impact factor: 4.052

2.  Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.

Authors:  C Niederau; R A Liddle; L D Ferrell; J H Grendell
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

3.  Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats.

Authors:  M Otsuki; S Tani; Y Okabayashi; M Fuji; T Nakamura; T Fujisawa; H Itoh
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

4.  The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat.

Authors:  J R Wisner; S Ozawa; I G Renner
Journal:  Int J Pancreatol       Date:  1989-05

5.  Hepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate.

Authors:  K Beckh; H Weidenbach; F Weidenbach; R Müller; G Adler
Journal:  Int J Pancreatol       Date:  1991 Nov-Dec

6.  Stimulation of pancreatic secretory process in the rat by low-molecular weight proteinase inhibitor. I. Dose-response study on enzyme content and secretion, cholecystokinin release and pancreatic fine structure.

Authors:  U Rausch; G Adler; H Weidenbach; F Weidenbach; D Rudolff; I Koop; H F Kern
Journal:  Cell Tissue Res       Date:  1987-01       Impact factor: 5.249

Review 7.  Candidate drugs against SARS-CoV-2 and COVID-19.

Authors:  Dwight L McKee; Ariane Sternberg; Ulrike Stange; Stefan Laufer; Cord Naujokat
Journal:  Pharmacol Res       Date:  2020-04-29       Impact factor: 7.658

Review 8.  Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2.

Authors:  Ali Karimian; Mohaddeseh Behjati; Mohammad Karimian
Journal:  Arch Virol       Date:  2022-08-08       Impact factor: 2.685

Review 9.  A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.

Authors:  Prerna Malik; Sonika Jain; Pankaj Jain; Jyoti Kumawat; Jaya Dwivedi; Dharma Kishore
Journal:  Arch Pharm (Weinheim)       Date:  2022-01-17       Impact factor: 4.613

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.